More good news on ceasing OI prophylaxis

Megan Nicholson, Megan Nicholson
Published: 05 March 2001

Preventative medicine for toxoplasma encephalitis may be safely ceased in individuals with sustained CD4 improvements, according to new data from the Swiss Cohort Study published in The Lancet.

The researchers followed 199 HIV-infected individuals, co-infected with Toxoplasma gondii, who had sustained CD4 counts above 200 cells for at least 12 weeks after commencing highly active antiretroviral therapy (HAART). None of the group had previously had toxoplasma encephalitis but all had been taking primary prophylaxis against T gondii. Median duration of prophylaxis was 26 months.

No cases of toxoplasma encephalitis occurred in the group after a median follow-up time of 1.4 years (range 0.1-2.4 years). Statistical analysis indicated that the incidence of toxoplasmosis in this study was below the frequency of an historical comparison group. Only four individuals in the study resumed prophylaxis when their CD4 levels fell below 200.

The authors concluded that stopping primary prophylaxis for toxoplasma encephalitis is safe among individuals with sustained immune recovery due to HAART. The findings suggest there may be a change to current guidelines issued by the US Centers for Disease Control which state that there is insufficient evidence to recommend cessation of prophylaxis against T gondii.

The findings add to a growing body of research which demonstrates that immune restoration due to HAART is effective in preventing a range of opportunistic infections. You can read more about this subject here on aidsmap.com in Prophylaxis and immune recovery in Restoring the immune system.

Reference

Furrer H et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Lancet 355:2217-2218, 2000.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.